A remarkable characteristic of OIPCs is their ability to transition between the solid crystalline phase and the liquid phase, ...

KaliVir Immunotherapeutics has dosed the first subject in a Phase I/Ib clinical trial for its new oncolytic immunotherapy, ...

The surge in the adoption of renewable energy, coupled with the rapid growth of the electric vehicle market in recent years ...

Organic ionic solid electrolytes (OIPCs) offer various desirable properties, with high potential as solid electrolytes for all-solid-state rechargeable batteries. However, they still need improvement ...

Global disinflation remains on track. A soft landing appears to be the most likely scenario for the U.S. economy. What does ...

Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial.The ongoing Phase 1 study is now enrolling ...

Black Diamond Therapeutics has deprioritized one of its two clinical-stage lung cancer contenders, jettisoned two executives ...

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's ...

To enhance patient outcomes and increased trial success, Convert Pharma is leveraging companion AI- and genetic biomarkers, a ...

Primary target patient population for the CBX-12 Phase 2 study is women with platinum-resistant or refractory ovarian cancer who are naïve to ...

Canadian health authorities cleared the firm's application to study ANS01 as treatment for advanced solid tumor patients harboring various MET alterations.

KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy therapeutics, today announced that the first patient ...